Merck & Co, INC 13F institutional holdings
Quarterly disclosures of US equity positions held by institutional managers with over $100 million under management.
NYSE
Merck & Co., Inc. has filed its quarterly 13F holdings report, detailing significant investments in various biotechnology companies as of March 31, 2026.
NYSE
Merck & Co. Inc. disclosed its institutional equity holdings for Q3 2025, totaling over $228 million across 13 positions.
NYSE
Merck & Co., Inc. disclosed its equity holdings for the second quarter of 2025, totaling over $215 million across 13 companies, primarily in the biotechnology and pharmaceutical sectors.
NYSE
Merck & Co.'s latest 13F filing reveals its holdings as of March 31, 2025, totaling over $164 million across various biotech and pharmaceutical companies.
NYSE
Merck & Co., Inc. reports its holdings for the quarter ended December 31, 2024, revealing significant investments in various biotechnology and pharmaceutical companies.